OncoMatch/Clinical Trials/NCT05998928
A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy
Is NCT05998928 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells for multiple myeloma.
Treatment: Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells — This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of bispecific BCMA-GPRC5D Chimeric antigen receptor (CAR) T-cells in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Multiple Myeloma
Performance status
ECOG 1–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: proteasome inhibitor
which at least include: one Proteasome Inhibitor (PI)
Must have received: immunomodulatory drug
which at least include: one Immunomodulatory Drug (IMiD)
Must have received: anti-CD38 monoclonal antibody
which at least include: one anti-CD38 monoclonal antibody
Cannot have received: anti-tumor therapies before apheresis
Patients received previous anti-tumor therapies before apheresis including following therapies: targeted therapies, epigenetics modulation drugs, other drugs or medical devices (invasive) of clinical trials, monoclonal antibodies, cytotoxic agents, PIs, IMiDs, radiotherapy
Lab requirements
Blood counts
Hemoglobin (Hb) ≥ 50 g/L without prior blood transfusion within 7 days
Kidney function
Serum creatinine ≤ 1.5×ULN, or creatinine clearance ≥ 60 mL/min
Liver function
Total bilirubin ≤ 1.5×ULN, alanine aminotransferase (ALT) ≤ 3 × ULN and aspartate aminotransferase (AST) ≤ 3 × ULN
Cardiac function
Left ventricular ejection fraction (LVEF) > 45%, without confirmed pericardiac effusion and abnormal electrocardiography with clinical significance; Baseline peripheral oxygen saturation > 92%; Without clinically significant pleural effusion
Liver, kidney and cardiopulmonary functions meet the following requirements: Total bilirubin ≤ 1.5×ULN, ALT ≤ 3 × ULN and AST ≤ 3 × ULN; Serum creatinine ≤ 1.5×ULN, or creatinine clearance ≥ 60 mL/min; Hemoglobin (Hb) ≥ 50 g/L without prior blood transfusion within 7 days; Baseline peripheral oxygen saturation > 92%; Corrected serum calcium ≤ 12.5 mg/dL (≤ 3.1 mmol/L) or free (ionized, ionic) calcium ≤ 6.5 mg/dL (≤ 1.6 mmol/L); Left ventricular ejection fraction (LVEF) > 45%, without confirmed pericardiac effusion and abnormal electrocardiography with clinical significance; Without clinically significant pleural effusion
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05998928 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-tumor therapies before apheresis disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages